Streetbeat News

Products Services

GNPX

Genprex's Chief Medical Officer provided updates on the Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials for lung cancer. These updates are crucial for the company's progress in developing new treatments.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:37 pm

FROG

JFrog has been added to the Department of Defense Enterprise Software Initiative's DevSecOps Agency Catalog, allowing defense organizations to integrate JFrog's software supply chain platform into U.S. government IT modernization efforts.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:15 pm

ABBV

EWC

AbbVie has announced that its drug EPKINLY has been listed on Ontario Health (Cancer Care Ontario) Formulary and Quebec's RAMQ for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients after two or more lines of therapy.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:15 pm

QCOM

Qualcomm and MediaTek are planning to expand their presence in the PC processor market by 2025 with their respective Arm chips, according to market sources.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:15 pm

TSM

TSMC is set to increase its CoWoS fab capacity to 60,000 wafers per month by 2025, following the acquisition of an Innolux 5.5G LCD factory. This capacity is expected to rise to 70,000-80,000 units in 2026.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:14 pm

AIRJ

Montana Technologies Corporation (NASDAQ:AIRJ) has signed a Memorandum of Understanding with TenX Investment to deploy its AirJoule technology in the UAE, focusing on water security and energy efficiency.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:11 pm

ORA

Ormat Technologies, Inc. (NYSE: ORA) has signed its first tolling agreements in Texas for two 60MW/120MWh energy storage facilities. These agreements secure seven years of fixed revenues and support the construction of a new 100MW/200MWh project, with all projects expected to be operational by the end of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:10 pm

GILD

The FDA has granted accelerated approval for Gilead Sciences' (NASDAQ:GILD) drug Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC). This approval follows Gilead's $4.3 billion acquisition of CymaBay Therapeutics. The approval is based on Phase 3 study data showing significant improvements in patients. However, continued approval is contingent on further clinical trials. Gilead's stock was down 0.04% in premarket trading.

Portfolio Pulse from Vandana Singh

August 15, 2024 | 1:09 pm

AVCNF

Avicanna Inc. reported an 85% YoY increase in Q2 revenue to CA$6.1 million. The company also completed two successful trials on drug candidates, showing significant improvements in patient conditions. Despite a net loss of CA$1.95 million, the adjusted EBITDA loss narrowed by 65%.

Portfolio Pulse from Nina Zdinjak

August 15, 2024 | 1:08 pm

GAUZ

Gauzy expects aggregated revenue of $240M over the next 10 years from aeronautic cockpit shading. New wins in Q2 2024 have increased Gauzy's market share to 95% in commercial aircraft and business jets. The company is well-positioned to expand in the $600M annual aircraft shading and lighting market.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:08 pm